Adriana Bonfigli

Adriana Bonfigli

Auto-generated profile, based on publicly available information

Adriana Bonfigli

Clinical Evaluations, ISPE, Milano, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
Enzo BerardescaEnzo Berardesca
Enzo Berardesca
ABAdriana Bonfigli
Adriana Bonfigli
BCBernard Cribier
Bernard Cribier
FFFrederic FLAMENT
Frederic FLAMENT
MVMarco Vicic
Marco Vicic
JTJerry K.L. Tan
Jerry K.L. Tan
Objective: This study assessed the efficacy and tolerability of M89 in patients with rosacea associated with erythema and sensitive skin. Methods: Intra-individual study in a split-face design comparing after 30 days M89 twice daily and usual skin care in 20 adult subjects with rosacea and sensitive skin. M89 contains 89% Vichy volcanic mineralizing water (VVMW) and 0.4% hyaluronic acid. It is hypoallergenic and contains no perfume and this convenes in rosacea. Contained minerals reinforce the natural defences of the skin in restoring the natural skin barrier, stimulating antioxidant activity and reducing inflammation, commonly observed in subjects with rosacea. Clinical evaluations included assessment of erythema, desquamation, papules and pustules, skin tightness, dryness, burning sensation, itching, stinging and stinging test as well as local tolerability. Instrumental evaluations included skin hydration and TEWL. Subject satisfaction was assessed at Days 15 and 30. Demodex density was assessed at Day 30. Results: A significant superiority of M89 over the standard skin care was observed for erythema, skin tightness and dryness (all P≤ 0.05) as early as Day 15, the skin stinging test was significantly in favour of M89 (P< 0.05 at Day 15 and P< 0.01 at Day 30) and for skin hydration (P< 0.0001) at Day 15 and 30 with no difference in mean Demodex density between M89 and usual skin care after 30 days. Tolerance was excellent and subject satisfaction very high. Conclusion: Study results concerning M89 are encouraging for its use either alone or as an adjuvant daily skin care to topical medication in patients with persistent centrofacial erythema of rosacea with no more than 3 papules and pustules.

1 January 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
Enzo BerardescaEnzo Berardesca
Enzo Berardesca
ABAdriana Bonfigli
Adriana Bonfigli
CCClaudia Cartigliani
Claudia Cartigliani
DKDelphine Kerob
Delphine Kerob
JTJerry K.L. Tan
Jerry K.L. Tan
Purpose: Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces skin defences against exposome factors. This study assessed the benefit of M89PF in subjects with rosacea associated with erythema and sensitive skin during the Covid-19 pandemic using protective face masks. Methods: M89PF was compared to usual skin care in a randomized, split-face study, for 30 days in subjects with rosacea associated with erythema and sensitive skin. Clinical evaluations included erythema, desquamation, skin tightness, dryness, burning sensation, itching, stinging, stinging test, and local tolerability. Instrument evaluations included erythema, skin hydration and TEWL. Subject satisfaction was also assessed. Results: Erythema significantly improved with M89PF at both time points (p< 0.01 at D15, and p< 0.001 at D30). Skin sensitivity assessed by the skin stinging test improved significantly (p< 0.01) with M89PF at D30, compared to baseline and usual skin care. Skin erythema, tightness, dryness, hydration and TEWL significantly improved (p≤ 0.05) with M89PF at D15 and D30, versus baseline and the untreated side. Subjects were highly satisfied with M89PF at D15 and D30. Tolerance was very good in all subjects. Conclusion: In subjects with rosacea, M89PF significantly reduces erythema, skin tightness, dryness and TEWL, and improves skin hydration and skin sensitivity, even when using protective masks. M89PF is well tolerated and received high satisfaction ratings. ClinicalTrials.gov. No: NCT05562661.

1 February 2002 in International Journal of Cosmetic Science
Verified
Journal Article
Closed access
PDF file
FDF. Distante
F. Distante
FSFilippo Scalise
Filippo Scalise
CRC. Rona
C. Rona
ABA. Bonfigli
A. Bonfigli
Joachim FluhrJoachim Fluhr
Joachim Fluhr
Enzo BerardescaEnzo Berardesca
Enzo Berardesca